Study of petosemtamab plus chemo for left-sided colorectal cancer
Treatments studied
This trial tests a new drug (petosemtamab) plus standard chemo to see if it works better than the current standard (cetuximab plus chemo) for people with advanced left-sided colorectal cancer that has not been treated yet. It is for patients whose cancer cells have no RAS or BRAF mutations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is in the left side of the colon or rectum (not right side).
- Your tumor cells do not have changes in the RAS or BRAF genes.
- You have not had any prior chemotherapy or other systemic therapy for advanced colorectal cancer.
- You are healthy enough to receive one of the standard chemotherapy regimens (FOLFOX or FOLFIRI).
- You do not have microsatellite instability-high (MSI-H) or a deficiency in mismatch repair (dMMR).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different combinations of chemotherapy drugs plus targeted therapy (cetuximab or bevacizumab) along with an immunotherapy drug (QL1706) as the first treatment for people with left-sided metastatic colorectal cancer that has no mutations in the KRAS, NRAS, or BRAF genes. The goal is to see which combination is more effective and safe.
This trial is testing a new combination of drugs (envafolimab, cetuxima-β, and chemotherapy) for people with a specific type of advanced colorectal cancer that has not been treated yet. The goal is to see if it is safe and works well.
This trial tests whether a combination of three drugs (cetuximabβ, envolimab, and mFOLFOX6) can help people with advanced colorectal cancer that has not been treated before. It is for people whose tumors have certain gene markers (RAS/BRAF wild-type and MSS).
This trial compares two different chemotherapy combinations, both including a targeted therapy called cetuximab, as a first treatment for people with a specific type of advanced left-sided colon cancer that cannot be surgically removed. The goal is to find out which combination works better.
This Phase 2 trial tests a combination of medicines (cetuximab, envafolimab, and chemotherapy) as the first treatment for certain left-sided metastatic colorectal cancers. It may help by slowing or shrinking the cancer in people whose tumor has no RAS/BRAF mutations and is microsatellite-stable (MSS).
This trial compares a standard chemotherapy combination (mFOLFOX6) plus a targeted drug (bevacizumab) with or without an immunotherapy (PD-1 antibody) for locally advanced colorectal cancer. It aims to see if adding the immunotherapy improves outcomes for patients with a specific tumor type (pMMR/MSS).
Hear when a new Left-sided Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.